Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: HD: An introduction PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Pipeline PART 08: Market segmentation by drug-class • Market scenario by drug-class • Antidopaminergics • Anticonvulsants • Antipsychotics • Antidepressants • Others PART 09: Geographical segmentation • Market segmentation by geography • HD therapeutics market in Americas • HD therapeutics market in EMEA • HD therapeutics market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Advances in biomedical sciences • Focus on regenerative therapies for mental disorders • Rising public interest toward mental health PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • F. Hoffmann-La Roche • H. Lundbeck • Prana Biotechnology • Teva Pharmaceutical Industries • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits  Exhibit 01: Parts of brain affected by HD Exhibit 02: Key facts about HD Exhibit 03: Prevalence and incidence of HD Exhibit 04: Neurotransmitter involved in pathogenesis of HD Exhibit 05: Market snapshot Exhibit 06: Global HD therapeutics market 2016-2021 ($ millions) Exhibit 07: Opportunity analysis of global HD therapeutics market Exhibit 08: Five forces analysis Exhibit 09: Pipeline landscape based on number of molecules 2016 Exhibit 10: HD: Key clinical trials Exhibit 11: Segmentation of global HD therapeutics market by drug-class Exhibit 12: Global HD therapeutics market share by drug-class Exhibit 13: Antidopaminergics used in HD Exhibit 14: Uses and side-effects of antidopaminergics Exhibit 15: Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions) Exhibit 16: Pharmacologic approach for the treatment of chorea Exhibit 17: Anticonvulsants used in HD Exhibit 18: Uses and side-effects of anticonvulsants Exhibit 19: Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions) Exhibit 20: Antipsychotics used in HD Exhibit 21: Uses and side-effects of antipsychotics Exhibit 22: Global HD therapeutics market by antipsychotics 2016-2021 ($ millions) Exhibit 23: Symptoms of depression associated with HD Exhibit 24: Global HD therapeutics market by antidepressants 2016-2021 ($ millions) Exhibit 25: Symptoms of mania associated with HD Exhibit 26: Global HD therapeutics market share by geography 2016 and 2021 Exhibit 27: Global HD therapeutics market revenue by geography 2016-2021 Exhibit 28: Global HD therapeutics market share by geography 2016-2021 Exhibit 29: HD therapeutics market scenario in different geographies Exhibit 30: Market scenario in Americas Exhibit 31: HD therapeutics market in Americas 2016-2021 ($ millions) Exhibit 32: Market scenario in EMEA Exhibit 33: HD therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 34: Market scenario in APAC Exhibit 35: HD therapeutics market in APAC 2016-2021 ($ millions) Exhibit 36: Planned clinical trials of iPS cell-based therapies Exhibit 37: Competitive structure analysis of global HD therapeutics market 2016 Exhibit 38: F. Hoffmann-La Roche: Key highlights Exhibit 39: F. Hoffmann-La Roche: Strength assessment Exhibit 40: F. Hoffmann-La Roche: Strategy assessment Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment Exhibit 42: H. Lundbeck: Key highlights Exhibit 43: H. Lundbeck: Strength assessment Exhibit 44: H. Lundbeck: Strategy assessment Exhibit 45: H. Lundbeck: Opportunity assessment Exhibit 46: Prana Biotechnology: Key highlights Exhibit 47: Prana Biotechnology: Strength assessment Exhibit 48: Prana Biotechnology: Strategy assessment Exhibit 49: Prana Biotechnology: Opportunity assessment Exhibit 50: Teva Pharmaceuticals: Key highlights Exhibit 51: Teva Pharmaceuticals: Strength assessment Exhibit 52: Teva Pharmaceuticals: Strategy assessment Exhibit 53: Teva Pharmaceuticals: Opportunity assessment

F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology, and Teva Pharmaceutical Industries. Other Prominent Vendors in the market are: Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.